T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness

Human Gene Therapy Methods

Volumn 25, Issue 6, 2014, Pages 345-357

  Lamers, Cor H J ^a   Van Steenbergen Langeveld, Sabine ^a   Van Brakel, Mandy ^a   Groot Van Ruijven, Corrien M ^a,b   Van Elzakker, Pascal M M L ^a,b   Van Krimpen, Brigitte ^a,b   Sleijfer, Stefan ^a   Debets, Reno ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; CD27 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; HLA A2 ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 21; L SELECTIN; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; T LYMPHOCYTE RECEPTOR; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; CD28 ANTIGEN; CD3 ANTIGEN; HYBRID PROTEIN; INTERLEUKIN DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR; MAGEC2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR PROTEIN;

ARTICLE; CANCER GENE THERAPY; CELL EXPANSION; CONTROLLED STUDY; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE TRANSFER; PHENOTYPE; SOLID TUMOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENICS; ADOPTIVE IMMUNOTHERAPY; CELL AGING; CYTOLOGY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; INTERFERON GAMMA RELEASE ASSAY; LYMPHOCYTE ACTIVATION; METABOLISM; TRANSPLANTATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CELL AGING; GENETIC VECTORS; HLA-A2 ANTIGEN; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA RELEASE TESTS; INTERLEUKINS; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 84918779798     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2014.051     Document Type: Article

References (53)

1. Bondanza, A., Valtolina, V., Magnani, Z., et al. (2006). Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 107, 1828-1836.
2. Brentjens, R.J., Davila, M.L., Riviere, I., et al. (2013). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38.
3. Brentjens, R.J., Riviere, I., Park, J.H., et al. (2011). Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817-4828.
4. Butler, M.O., Friedlander, P., Milstein, M.I., et al. (2011). Establishment of antitumor memory in humans using in vitroeducated CD8 + T cells. Sci. Transl. Med. 3, 80ra34.
5. Cieri, N., Camisa, B., Cocchiarella, F., et al. (2013). IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121, 573-584.
6. Davila, M.L., Riviere, I., Wang, X., et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25.
7. Duarte, R.F., Chen, F.E., Lowdell, M.W., et al. (2002). Functional impairment of human T-lymphocytes following PHAinduced expansion and retroviral transduction: implications for gene therapy. Gene Ther. 9, 1359-1368.
8. Gattinoni, L., and Restifo, N.P. (2013). Moving T memory stem cells to the clinic. Blood 121, 567-568.
9. Gattinoni, L., Klebanoff, C.A., Palmer, D.C., et al. (2005). Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8 + T cells. J. Clin. Invest. 115, 1616-1626.
10. Gattinoni, L., Powell, D.J., Jr., Rosenberg, S.A., and Restifo, N.P. (2006). Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6, 383-393.
11. Gattinoni, L., Zhong, X.S., Palmer, D.C., et al. (2009). Wnt signaling arrests effector T cell differentiation and generates CD8 + memory stem cells. Nat. Med. 15, 808-813.
12. Gattinoni, L., Lugli, E., Ji, Y., et al. (2011). A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290-1297.
13. Gilham, D.E., Debets, R., Pule, M., et al. (2012). CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol. Med. 18, 377-384.
14. Grupp, S.A., Kalos, M., Barrett, D., et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518.
15. Hinrichs, C.S., Spolski, R., Paulos, C.M., et al. (2008). IL-2 and IL-21 confer opposing differentiation programs to CD8 + T cells for adoptive immunotherapy. Blood 111, 5326-5333.
16. Hinrichs, C.S., Borman, Z.A., Cassard, L., et al. (2009). Adoptively transferred effector cells derived from naive rather than central memory CD8 + T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. USA 106, 17469-17474.
17. Hinrichs, C.S., Borman, Z.A., Gattinoni, L., et al. (2011). Human effector CD8 + T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117, 808-814.
18. Hollyman, D., Stefanski, J., Przybylowski, M., et al. (2009). Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J. Immunother. 32, 169-180.
19. Huang, J., Khong, H.T., Dudley, M.E., et al. (2005). Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother. 28, 258-267.
20. Huarte, E., Fisher, J., Turk, M.J., et al. (2009). Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett. 285, 80-88.
21. Johnson, L.A., Morgan, R.A., Dudley, M.E., et al. (2009). Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546.
22. Kalos, M., Levine, B.L., Porter, D.L., et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia. Sci Transl Med 3, 95ra73.
23. Kaneko, S., Mastaglio, S., Bondanza, A., et al. (2009). IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 113, 1006-1015.
24. Kershaw, M.H., Westwood, J.A., Parker, L.L., et al. (2006). A phase I study on adoptive immunotherapy using genemodified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115.
25. Klebanoff, C.A., Finkelstein, S.E., Surman, D.R., et al. (2004). IL-15 enhances the in vivo antitumor activity of tumorreactive CD8 + T cells. Proc. Natl. Acad. Sci. USA 101, 1969-1974.
26. Klebanoff, C.A., Gattinoni, L., Torabi-Parizi, P., et al. (2005). Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. USA 102, 9571-9576.
27. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720.
28. Kunert, A., Straetemans, T., Govers, C., et al. (2013). TCRengineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieu. Front Immunol 4, 363.
29. Lamers, C.H., Van De Griend, R.J., Braakman, E., et al. (1992). Optimization of culture conditions for activation and largescale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy. Int. J. Cancer 51, 973-979.
30. Lamers, C.H., Willemsen, R.A., Luider, B.A., et al. (2002). Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther. 9, 613-623.
31. Lamers, C., Van Elzakker, P., Langeveld, S., et al. (2006a). Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene. Cytotherapy 8, 542-553.
32. Lamers, C.H., Sleijfer, S., Vulto, A.G., et al. (2006b). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20-e22.
33. Lamers, C.H., Willemsen, R.A., Van Elzakker, P., et al. (2006c). Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer. Cancer Gene Ther. 13, 503-509.
34. Lamers, C.H., Willemsen, R., Van Elzakker, P., et al. (2011). Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117, 72-82.
35. Lamers, C.H., Sleijfer, S., Van Steenbergen, S., et al. (2013a). Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity. Mol. Ther. 21, 904-912.
36. Lamers, C.H., Van Elzakker, P., Van Steenbergen, S.C., et al. (2013b). Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells. Cytotherapy 15, 620-626.
37. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., et al. (2014). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. Early Online Publication. DOI: 10.1016/S0140-6736(14)61403-3
38. Liu, S., Riley, J., Rosenberg, S., and Parkhurst, M. (2006). Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy. J. Immunother. 29, 284-293.
39. Lurquin, C., Lethe, B., De Plaen, E., et al. (2005). Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med. 201, 249-257.
40. Markley, J.C., and Sadelain, M. (2010). IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cellmediated rejection of systemic lymphoma in immunodeficient mice. Blood 115, 3508-3519.
41. Maude, S.L., Frey, N., Shaw, P.A., et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517.
42. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129.
43. Pouw, N., Treffers-Westerlaken, E., Kraan, J., et al. (2010a). Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol. Immunother. 59, 921-931.
44. Pouw, N., Treffers-Westerlaken, E., Mondino, A., et al. (2010b). TCR gene-engineered T cell: Limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity. Mol. Immunol. 47, 1411-1420.
45. Robbins, P.F., Dudley, M.E., Wunderlich, J., et al. (2004). Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173, 7125-7130.
46. Robbins, P.F., Morgan, R.A., Feldman, S.A., et al. (2011). Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917-924.
47. Rosenberg, S.A., Yang, J.C., Sherry, R.M., et al. (2011). Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin. Cancer Res. 17, 4550-4557.
48. Schneiders, F.L., De Bruin, R.C., Van Den Eertwegh, A.J., et al. (2012). Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: updated analysis with 10-year follow-up. J. Clin. Oncol. 30, 567-570.
49. Straetemans, T., Van Brakel, M., Van Steenbergen, S., et al. (2012). TCR gene transfer: MAGE-C2/HLA-A2 and MAGEA3/HLA-DP4 epitopes as melanoma-specific immune targets. Clin. Dev. Immunol. 2012, 586314.
50. Till, B.G., Jensen, M.C., Wang, J., et al. (2008). Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261-2271.
51. Uemura, H., Okajima, E., Debruyne, F.M.J., and Oosterwijk, E. (1994). Internal image antiidiotype antibodies related to renal-cell carcinoma-associated antigen G250. Int. J. Cancer 56, 609-614.
52. Wang, X., Berger, C., Wong, C.W., et al. (2011). Engraftment of human central memory-derived effector CD8 + T cells in immunodeficient mice. Blood 117, 1888-1898.
53. Yang, S., Ji, Y., Gattinoni, L., et al. (2013). Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol. Immunother. 62, 727-736.